Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib

ORR: Objective response rate; DCR: Disease control rate; DOR: Duration of response; PFS: Progression-free survival 1 Piotrowska Z, et al. JCO 2023 2 DCR= (PR+SD) / response-evaluable patients PR: Partial response; SD: Stable disease Zipalertinib demonstrated a manageable safety profile, similar to what has been previously reported. There were no grade 4 or grade 5 treatment-related adverse events. CAMBRIDGE, Mass., June 01, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceuti ...